CELLINK is the first bioink company in the world and the leading 3D bioprinter provider that focuses on the development and commercialisation of bioprinting technologies that allow researchers and scientists to 3D bioprint human organs and tissues for the development of pharmaceutical and cosmetic treatments.
CELLINK’s innovative and patent pending bioinks are biomaterial innovations that enable human cells to grow and thrive such as they would in the human body. Today, the company’s disruptive technology platform is being utilised to print tissues such as cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, in just 24 months, been able to commercialise products into more than 450 prestigious labs such as Harvard, MIT, Princeton, VT, and the FDA in over 45 countries around the world. CELLINK has been awarded many prestigious awards such as Start-up of the Year, Inventors of the Year, and recently, one of the co-founders was placed on the Forbes 30 Under 30 list while the other co-founder had a prestigious TEDx Talk.
To read more about CELLINK, please visit: www.cellink.com
